A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
about
Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship.Future Directions in Imaging Neurodegeneration.Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population.Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementiaModeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data SetTau PET imaging: present and future directions.Repetitive head impact exposure and later-life plasma total tau in former National Football League players.Functional network integrity presages cognitive decline in preclinical Alzheimer disease.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.Neurologic Applications of PET/MR Imaging.Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals.Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load.A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.On the path to 2025: understanding the Alzheimer's disease continuum.Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.Alzheimer disease: CSF biomarkers for Alzheimer disease - approaching consensus.Diagnostic Accuracy of Memory Measures in Alzheimer's Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis.Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.Genetic Biomarkers on Age-Related Cognitive Decline.Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease.Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps.Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease.Declines in Connected Language Are Associated with Very Early Mild Cognitive Impairment: Results from the Wisconsin Registry for Alzheimer's Prevention.The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions.Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.Brain Biomarkers in Familial Alzheimer's Disease Mouse Models.
P2860
Q30101023-292ED32C-4A22-4AD0-83CB-EAB564D6A6CBQ31162702-2EAD536A-441A-4F4A-9E17-563AA6CB6D7EQ33648361-64319E54-E0AB-4A53-B2C2-B716D4C25B7EQ33763640-0748AFC8-F519-422C-BE6F-C29187E4B37DQ33926397-451D1ECD-755E-4D22-B9F6-93E8CA1A743DQ34680852-29152870-2A89-4AF1-99FC-91EDAF8AB26CQ37645272-3B159601-4831-4151-8A19-ED02EB88A178Q38673547-7D69C84E-707E-46C3-A3AD-381FE1BB7A6CQ38739937-79A840B6-BAEC-4C38-B076-0B1803D67491Q38773523-6FAAA891-56BE-4A4D-9305-40C54840740AQ38812890-BC467395-07F1-47C6-A6A8-79C3004D3E3CQ38846608-FDF6848D-2D10-4328-A323-45DDC08C66CAQ38896981-4AACCEA1-0778-4F85-8A9E-6E3D3B9C71B1Q38990773-00939693-E236-4C25-BC1E-A1CBE89623A9Q39034863-6295EF12-5DF0-4BC9-AA9A-1FD893B43CFAQ39451637-0DFED88F-62CE-4A43-AFC4-928F5E2440BDQ41084541-6CF9FDAB-E3A5-4007-AD6C-BC735FF2B7C7Q41318515-1BA17A89-22E9-49C5-8A7D-8E6E0045E55DQ41566620-9B13B1CC-5FEC-465E-8395-6950F930C073Q41600997-EA90B79D-860B-4FE9-880C-4BE82EB43E25Q41691372-647A0233-5CF0-4C8B-B94E-F36AF3D29B83Q45949141-AF9573B9-7F60-4397-86A1-5A25DAEB1D84Q46254853-3C0B74BD-D83E-47D1-B917-8F1B7063D236Q46320596-0BF5003C-AA55-4E9A-BC78-E1D29A2A947FQ46523983-CBDD1502-4C3B-40AF-B5F0-234993E5C662Q46678949-AC92D81D-CB64-4746-A6EB-4E4C95647F69Q47107551-5E70B2C7-8B7F-4267-A2DE-EA2F3233E3B2Q47123978-BAA26903-4EB5-4E85-A5B1-57F490532F17Q47161807-2F6B9F8A-0143-4893-AC24-C104038B5F48Q47225592-88774D7A-9F5D-4140-9FED-99BDEE500584Q47398802-EF5E3E10-3747-4A25-B0FF-1270E5CC5005Q47560023-3147206A-5A43-4A7E-8445-AA86DBCB7089Q47560282-86536646-1E33-4891-B5F1-789FE8337238Q47587631-55CA790D-057D-4B71-B8D3-78487F8A4FB5Q47604596-ABE3EE47-C5A0-4E42-B1CF-DDA10BE2F647Q47610192-71A1B147-DB6A-4ECD-B83E-45B5458E18B3Q47644432-5ACD9A28-282F-4524-A6D3-5CBED915F2ACQ47646484-73B351AB-C076-4D8F-B825-4A94BF458D95Q47655041-DCE0E52C-C7DA-4591-AFBA-D4E75A8479B3Q48108053-EE3EC5F3-7B39-4038-BD28-802C7EE88A9C
P2860
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@ast
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@en
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@nl
type
label
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@ast
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@en
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@nl
prefLabel
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@ast
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@en
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
@en
P2093
Giovanni B Frisoni
Howard H Feldman
Keith A Johnson
Reisa A Sperling
William J Jagust
P2860
P304
P3181
P356
10.1212/WNL.0000000000002923
P407
P50
P5008
P577
2016-08-02T00:00:00Z